Trending...
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI - 144
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty - 129
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage - 101
SAN DIEGO ~ Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has appointed Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand's board.
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
- New Media Film Festival Announces Winners
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- DetailAxis Unveils it's 'Business Engine': Powerful AI Systems for Auto Appearance Pros
- California: Governor Newsom announces appointments 7.2.25
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
- Digital Watchdog Launches New myDW Cloud Services
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
Filed Under: Business
0 Comments
Latest on The Californer
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Riser Music's LYKN Adds India, Mexico & U.s. Dates To "unleashed" World Tour
- Auraya Launches EVA Forensics on NICE CXexchange
- Crypto Corner Shop Launches Walletless Crypto Commerce Marketplace For Goods/Services Worldwide
- Immigrant Couple from Modesto Wins Prestigious Awards at the SF Wine and Spirits Competition
- Prolific Hollywood Actor Phillip E. Walker-MFA is Experiencing His Best Year of Employment Ever
- TOMORROW: Governor Newsom to announce $750 million tax credit for film and TV made in California
- California: National Guard firefighters finally back to work — but Trump's militarization of LA has pulled cops from the street and teachers out of classrooms
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Independent Financial Group Expands East Coast Recruiting Reach with the Hiring of Former Osaic Executive Bruce Levitus
- Talbot Law Group, P.C. Announces Super Lawyers® 2025 Honors for Matthew B. Talbot and Mark E. Miyasaki
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- California: Governor Newsom challenges President Trump to adopt model executive order to help 'Make America Rake Again'
- Long Beach Airport Named Number Two Airport in Nation by The Washington Post
- Dedeaux Properties Begins Construction on Truck Terminal and Industrial Outdoor Storage Facility
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- Live Courageously Hosts Ann-Marie Murrell, Author, Journalist, Former Political Commentator